Posted by Michael Wonder on 02 Feb 2021
Celltrion Healthcare receives Health Canada marketing authorization for world's first subcutaneous formulation of infliximab, Remsima SC, for the treatment of people with rheumatoid arthritis
1 February 2021 - This novel formulation provides an alternative administration option for Canadian physicians and their patients.
Celltrion Healthcare Canada announced today that Health Canada has granted a notice of compliance for Remsima SC (CT-P13 SC) in Canada for the treatment of adult patients with rheumatoid arthritis.
